Pfizer's BRAFTOVI combo cut death risk by 51% and more than doubled survival in BRAF-mutant colorectal cancer in a Phase 3 ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

Pfizer Inc. closed 25.65% short of its 52-week high of $31.54, which the company achieved on July 30th.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Pfizer’s stock took a sharp dip on May 28, dropping over 2% to $23.12 by the afternoon. The stock opened flat at $23.61 but ...

Shares of Pfizer Inc. PFE slid 1.82% to $23.18 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.56% to 5,888.55 and Dow ...

Pfizer Limited’s stock price surged 28% last month and 18% over the past year, raising eyebrows despite subdued future growth ...

Pfizer remains a strong Buy with robust cost controls, EPS growth, and a promising pipeline, despite challenges. See more on ...

Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

Second, Pfizer's forward dividend yield stands at 7.47%. At first glance, the drugmaker's dividend payout ratio of 122.5% ...

Pfizer's (NYSE: PFE) management team is confident in its 2025 opportunities. Where to invest $1,000 right now? Our analyst ...